• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    MBX Biosciences Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    5/12/25 8:11:46 AM ET
    $MBX
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $MBX alert in real time by email
    8-K
    0001776111false00017761112025-05-122025-05-12

     

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    WASHINGTON, D.C. 20549

     

    FORM 8-K

     

    CURRENT REPORT

    Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

    Date of Report (Date of earliest event reported): May 12, 2025

     

     

    MBX Biosciences, Inc.

    (Exact name of Registrant as Specified in Its Charter)

     

     

    Delaware

    001-42272

    84-1882872

    (State or Other Jurisdiction
    of Incorporation)

    (Commission File Number)

    (IRS Employer
    Identification No.)

     

     

     

     

     

    11711 N. Meridian Street

    Suite 300

     

    Carmel, Indiana

     

    46032

    (Address of Principal Executive Offices)

     

    (Zip Code)

     

    Registrant’s Telephone Number, Including Area Code: (317) 659-0200

     

    Not Applicable

    (Former Name or Former Address, if Changed Since Last Report)

     

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

    ☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
    ☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
    ☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
    ☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

    Securities registered pursuant to Section 12(b) of the Act:


    Title of each class

     

    Trading
    Symbol(s)

     


    Name of each exchange on which registered

    Common Stock, $0.0001 par value per share

     

    MBX

     

    Nasdaq Global Select Market

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

    Emerging growth company ☒

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

     


    Item 2.02 Results of Operations and Financial Condition.

    On May 12, 2025, MBX Biosciences, Inc. (the "Company") announced its financial results for the quarter ended March 31, 2025. A copy of the press release is being furnished as Exhibit 99.1 to this Current Report on Form 8-K.

    The information included under Item 2.02 of this Current Report on Form 8-K (including Exhibit 99.1 attached hereto), is intended to be furnished and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, and shall not be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.

    Item 9.01 Financial Statements and Exhibits.

    (d) Exhibits.

     

     

    Exhibit No.

    Description

    99.1

    Press Release Issued by MBX Biosciences, Inc. on May 12, 2025

    104

    Cover Page Interactive Data File (embedded within the Inline XBRL document)

     


    SIGNATURES

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

     

     

     

    MBX Biosciences, Inc.

     

     

     

     

    Date:

    May 12, 2025

    By:

    /s/ P. Kent Hawryluk

     

     

     

    President and Chief Executive Officer (Principal Executive Officer)

     


    Get the next $MBX alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $MBX

    DatePrice TargetRatingAnalyst
    4/10/2025$38.00Mkt Outperform
    Citizens JMP
    10/8/2024$44.00Buy
    Guggenheim
    10/8/2024$40.00Buy
    Stifel
    10/8/2024$35.00Buy
    Jefferies
    10/8/2024$30.00Overweight
    JP Morgan
    More analyst ratings

    $MBX
    Leadership Updates

    Live Leadership Updates

    See more
    • MBX Biosciences Reports First Quarter 2025 Financial Results and Recent Corporate Highlights

      Topline results for the Phase 2 Avail™ evaluating canvuparatide in patients with hypoparathyroidism expected in 3Q 2025 Investigational New Drug submission for MBX 4291 on track for 2Q 2025 $240.8 million in cash, cash equivalents and marketable securities as of March 31, 2025; expected to support operations into mid-2027 CARMEL, Ind., May 12, 2025 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc. (NASDAQ:MBX), a clinical-stage biopharmaceutical company focused on the discovery and development of novel precision peptide therapies for the treatment of endocrine and metabolic disorders, today reported financial results for the first quarter ended March 31, 2025, and highlighted recent corporate

      5/12/25 8:00:00 AM ET
      $MBX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • MBX Biosciences Appoints Veteran Pharmaceutical Executive Steve Hoerter to Board of Directors

      CARMEL, Ind., April 07, 2025 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc. (NASDAQ:MBX), a clinical-stage biopharmaceutical company focused on the discovery and development of novel precision peptide therapies for the treatment of endocrine and metabolic disorders, today announced the appointment of Steve Hoerter as an independent director to the Company's Board of Directors. Mr. Hoerter brings over three decades of pharmaceutical commercialization and executive leadership experience as well as a proven track record of building and growing life science companies. "I am thrilled to welcome Steve Hoerter to the Company's Board as an independent director," said Kent Hawryluk, President and Chief

      4/7/25 8:00:00 AM ET
      $MBX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • MBX Biosciences Announces Additions to Leadership Team

      Chatan Charan, Ph.D. appointed as Senior Vice President, Pharmaceutical Development and CMC Mark Hope appointed as Senior Vice President, Regulatory and Quality CARMEL, Ind., March 05, 2025 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc. (NASDAQ:MBX), a clinical-stage biopharmaceutical company focused on the discovery and development of novel precision peptide therapies for the treatment of endocrine and metabolic disorders, today announced the appointments of Chatan Charan, Ph.D. as Senior Vice President, Pharmaceutical Development and Chemistry, Manufacturing and Controls (CMC) and Mark Hope as Senior Vice President, Regulatory and Quality. "We are excited to welcome Chatan and Mark, who wi

      3/5/25 8:00:00 AM ET
      $MBX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $MBX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Citizens JMP initiated coverage on MBX Biosciences with a new price target

      Citizens JMP initiated coverage of MBX Biosciences with a rating of Mkt Outperform and set a new price target of $38.00

      4/10/25 12:42:19 PM ET
      $MBX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Guggenheim initiated coverage on MBX Biosciences with a new price target

      Guggenheim initiated coverage of MBX Biosciences with a rating of Buy and set a new price target of $44.00

      10/8/24 7:30:45 AM ET
      $MBX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Stifel initiated coverage on MBX Biosciences with a new price target

      Stifel initiated coverage of MBX Biosciences with a rating of Buy and set a new price target of $40.00

      10/8/24 7:30:45 AM ET
      $MBX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $MBX
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Pescovitz Ora H. bought $45,312 worth of shares (7,693 units at $5.89), increasing direct ownership by 46% to 24,329 units (SEC Form 4)

      4 - MBX Biosciences, Inc. (0001776111) (Issuer)

      4/10/25 8:39:55 AM ET
      $MBX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Gordon Carl L bought $2,020,756 worth of shares (190,672 units at $10.60) (SEC Form 4)

      4 - MBX Biosciences, Inc. (0001776111) (Issuer)

      2/19/25 5:56:33 PM ET
      $MBX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Orbimed Advisors Llc bought $2,020,756 worth of shares (190,672 units at $10.60) (SEC Form 4)

      4 - MBX Biosciences, Inc. (0001776111) (Issuer)

      2/19/25 5:52:03 PM ET
      $MBX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $MBX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by MBX Biosciences Inc.

      SC 13G - MBX Biosciences, Inc. (0001776111) (Subject)

      11/8/24 10:52:39 AM ET
      $MBX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by MBX Biosciences Inc.

      SC 13G - MBX Biosciences, Inc. (0001776111) (Subject)

      11/1/24 5:38:56 PM ET
      $MBX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13D filed by MBX Biosciences Inc.

      SC 13D - MBX Biosciences, Inc. (0001776111) (Subject)

      9/23/24 6:07:21 PM ET
      $MBX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $MBX
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • MBX Biosciences Reports First Quarter 2025 Financial Results and Recent Corporate Highlights

      Topline results for the Phase 2 Avail™ evaluating canvuparatide in patients with hypoparathyroidism expected in 3Q 2025 Investigational New Drug submission for MBX 4291 on track for 2Q 2025 $240.8 million in cash, cash equivalents and marketable securities as of March 31, 2025; expected to support operations into mid-2027 CARMEL, Ind., May 12, 2025 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc. (NASDAQ:MBX), a clinical-stage biopharmaceutical company focused on the discovery and development of novel precision peptide therapies for the treatment of endocrine and metabolic disorders, today reported financial results for the first quarter ended March 31, 2025, and highlighted recent corporate

      5/12/25 8:00:00 AM ET
      $MBX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • MBX Biosciences to Participate in Citizens and RBC May Investor Conferences

      CARMEL, Ind., April 22, 2025 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc. (NASDAQ:MBX), a clinical-stage biopharmaceutical company focused on the discovery and development of novel precision peptide therapies for the treatment of endocrine and metabolic disorders, today announced that Kent Hawryluk, President and Chief Executive Officer, will present at and participate in the Citizens Life Sciences Conference on May 7 and the RBC 2025 Global Healthcare Conference on May 21. The Citizens Life Sciences Conference Date: Wednesday, May 7, 2025Format: Fireside chat and 1x1 meetingsTime: 3:00 p.m. – 3:25 p.m. ETLocation: New York, NY The RBC 2025 Global Healthcare Conference Date: Wednesday, Ma

      4/22/25 8:00:00 AM ET
      $MBX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • MBX Biosciences Appoints Veteran Pharmaceutical Executive Steve Hoerter to Board of Directors

      CARMEL, Ind., April 07, 2025 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc. (NASDAQ:MBX), a clinical-stage biopharmaceutical company focused on the discovery and development of novel precision peptide therapies for the treatment of endocrine and metabolic disorders, today announced the appointment of Steve Hoerter as an independent director to the Company's Board of Directors. Mr. Hoerter brings over three decades of pharmaceutical commercialization and executive leadership experience as well as a proven track record of building and growing life science companies. "I am thrilled to welcome Steve Hoerter to the Company's Board as an independent director," said Kent Hawryluk, President and Chief

      4/7/25 8:00:00 AM ET
      $MBX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $MBX
    SEC Filings

    See more

    $MBX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Amendment: SEC Form SCHEDULE 13G/A filed by MBX Biosciences Inc.

      SCHEDULE 13G/A - MBX Biosciences, Inc. (0001776111) (Subject)

      5/12/25 10:44:44 AM ET
      $MBX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 10-Q filed by MBX Biosciences Inc.

      10-Q - MBX Biosciences, Inc. (0001776111) (Filer)

      5/12/25 8:19:03 AM ET
      $MBX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • MBX Biosciences Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - MBX Biosciences, Inc. (0001776111) (Filer)

      5/12/25 8:11:46 AM ET
      $MBX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Pescovitz Ora H. bought $45,312 worth of shares (7,693 units at $5.89), increasing direct ownership by 46% to 24,329 units (SEC Form 4)

      4 - MBX Biosciences, Inc. (0001776111) (Issuer)

      4/10/25 8:39:55 AM ET
      $MBX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Director Hoerter Steven L.

      4 - MBX Biosciences, Inc. (0001776111) (Issuer)

      4/9/25 8:27:25 AM ET
      $MBX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 3 filed by new insider Hoerter Steven L.

      3 - MBX Biosciences, Inc. (0001776111) (Issuer)

      4/7/25 8:24:23 AM ET
      $MBX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $MBX
    Financials

    Live finance-specific insights

    See more
    • MBX Biosciences Announces Positive Phase 1 Topline Results for MBX 1416 for the Treatment of Post-bariatric Hypoglycemia

      Phase 1 results support proceeding to Phase 2 in patients with post-bariatric hypoglycemia (PBH), which is expected to begin in 2H 2025 Phase 1 trial in healthy volunteers showed MBX 1416 was generally well-tolerated with a favorable safety profile Pharmacokinetic results demonstrated sustained dose-dependent exposure and support once-weekly dosing Company to host conference call to discuss results today at 8:30 am ET CARMEL, Ind., Jan. 07, 2025 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc. (NASDAQ:MBX), a clinical-stage biopharmaceutical company focused on the discovery and development of novel precision peptide therapies for the treatment of endocrine and metabolic disorders, today annou

      1/7/25 7:00:00 AM ET
      $MBX
      Biotechnology: Pharmaceutical Preparations
      Health Care